Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 84Colorectal Neoplasms 42Rectal Neoplasms 40Carcinoma, Non-Small-Cell Lung 27Esophageal Neoplasms 24Esophageal Squamous Cell Carcinoma 23Stomach Neoplasms 19Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Colonic Neoplasms 17Pancreatic Neoplasms 15Adenocarcinoma Of Esophagus 15Sarcoma 14Prostatic Neoplasms 13Neoplasm Metastasis 13Neoplasms 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Carcinoma, Hepatocellular 11Inflammatory Breast Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Osteosarcoma 8Fallopian Tube Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Multiple Myeloma 6Glioblastoma 6Carcinoma, Renal Cell 6

Interventions

Trastuzumab 30pertuzumab 16Docetaxel 16pyrotinib 11Paclitaxel 7Carboplatin 5Capecitabine 5Ado-Trastuzumab Emtansine 4tucatinib 3trastuzumab deruxtecan 2atezolizumab 2Protons 2Fulvestrant 2pegfilgrastim 1palbociclib 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-positive Breast Cancer × Neoadjuvant Therapy × Clear all
NCT06832904 2025-02-18

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
33 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡